The injection form typically achieves more consistent serum levels and may provide slightly faster appetite suppression for some users, while the oral option offers convenience and eliminates needle-related anxiety
The approval was granted under the FDAs Commissioners National Priority Voucher pilot programme, which expedites review for priority therapies
#obesity #glp1 #healthcareinnovation #healthcaredata Jonathan Rossmans Post Fun fact from a data deep dive that I helped work on: Medicaid spending on GLP-1s has grown exponentially over the past five years with 36 states now covering at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda) Why
Many employers, in an effort to keep premium costs down, opt out of this coverage entirely
Knac, E
Compile Your Health History Some people may not be a good fit for certain GLP-1sfor example, those with a personal or family history of Medullary Thyroid Cancer (MTC) or those who take other blood-sugar regulating medicationscombining the two can result in low blood sugar levels